Presente y futuro del tratamiento de segunda línea del cáncer de pulmón no microcítico

40 / 48

… is suffocating research, is leading to trials being
done in haste without sufficient preclinical
investigation, and is an inefficient use of funds spent
on research and development.
THE SHADOWS…
Lancet Oncol 2017